{"id":"W2070825440","doi":"10.1016/s1470-2045(15)70122-1","title":"Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial","year":2015,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Cutaneous Melanoma Detection and Management","field":"Medicine","cited_by":1255,"is_retracted":false,"has_abstract":false,"ca_institutions":"Alberta Cancer Foundation","funders":"National Cancer Institute; Bristol-Myers Squibb","keywords":"Ipilimumab; Placebo; Medicine; Adjuvant; Oncology; Melanoma; Internal medicine; Stage (stratigraphy); Resection; Surgery; Cancer; Immunotherapy; Cancer research; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1165948738888528,"score_gpt":0.3704590522131933,"score_spread":0.2538641783243404,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}